Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Copy of Newspaper Publication
8 August 2025 - PAR Drugs reports Q1 FY26 standalone unaudited results: Net profit Rs 3.33 Cr, income Rs 26.05 Cr.
-
Outcome of Board Meeting
7 August 2025 - Q1 FY2026 standalone financial results approved; revenue Rs 2604.64L, profit Rs 332.81L; banking facility renewed Rs 161L.
-
Updates
7 August 2025 - Q1 FY2026 unaudited standalone results: Revenue Rs 2604.64L, Profit Rs 332.81L, EPS Rs 2.70, no exceptions.
-
Outcome of Board Meeting
7 August 2025 - Par Drugs reports Q1 FY26 standalone profit of Rs. 332.81L; approves banking renewal, publishes results.
-
Outcome of Board Meeting
7 August 2025 - Par Drugs reports Q1 FY26 standalone profit of Rs 332.81L; Board approves financials and banking renewal.
Annual reports
Concalls
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment